色氨酸代谢酶在子宫内膜癌分子亚型中的预后与免疫意义
本研究对570例子宫内膜癌按MMRd、p53mut和NSMP分子分型,用免疫组化检测IDO1、TDO2、IL4I1等表达与免疫微环境的关系。高IDO1与NSMP和p53mut肿瘤DSS改善相关,高TDO2间质表达预测NSMP患者DSS降低,CD163:CD8比值高独立预测p53mut肿瘤DSS更差。
要点
- 高IDO1肿瘤表达与NSMP和p53mut肿瘤DSS改善相关(p < 0.05)。
- 高TDO2间质表达预测NSMP患者DSS降低(p < 0.05)。
- 高CD163:CD8比值独立预测p53mut肿瘤DSS更差(p < 0.05)。
核心结论
- 色氨酸-犬尿氨酸酶以亚型特异性方式塑造子宫内膜癌免疫景观,高IDO1与p53mut和NSMP病例良好结局相关,而TDO2预测不良预后,CD163:CD8比值是独立的不良生存标志。
研究设计与样本
- 对570例子宫内膜癌进行分类为错配修复缺陷(MMRd)、p53突变(p53mut)或无特定分子谱(NSMP)。
- 用免疫组化评估IDO1、TDO2、IL4I1、PD-L1、犬尿氨酸及免疫标志物(CD8、FOXP3、CD68、CD163),并用QuPath在肿瘤和间质区室定量。
- 用相关性检验、Kaplan-Meier和Cox回归分析疾病特异性生存(DSS)关联。
主要发现
- IDO1、TDO2和IL4I1与免疫浸润密度强相关。
- 高IDO1肿瘤表达与NSMP和p53mut肿瘤DSS改善相关(p < 0.05),符合「炎症型」表型。
- 高TDO2间质表达预测NSMP患者DSS降低(p < 0.05)。
- 高IL4I1肿瘤表达与MMRd肿瘤DSS改善相关(p < 0.05)。
- 高CD163:CD8比值独立预测p53mut肿瘤DSS更差(p < 0.05)。
临床怎么用
- 作者认为这些发现支持联合IDO1/TDO2双重抑制或靶向IL4I1-芳香烃受体(AhR)轴的治疗策略,以增强子宫内膜癌免疫治疗疗效。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The kynurenine pathway is a key immunosuppressive mechanism implicated in resistance to immune checkpoint inhibitors (ICIs). This study investigated expression of tryptophan-metabolising enzymes (IDO1, TDO2, IL4I1) and their relationship with the immune microenvironment across molecular subtypes of endometrial cancer (EC). METHODS: A cohort of 570 ECs was classified as mismatch repair-deficient (MMRd), p53-mutant (p53mut), or no specific molecular profile (NSMP). Expression of IDO1, TDO2, IL4I1, PD-L1, kynurenine, and immune markers (CD8, FOXP3, CD68, CD163) was assessed by immunohistochemistry and quantified in tumour and stromal compartments using QuPath. Associations with disease-specific survival (DSS) were analysed using correlation testing, Kaplan-Meier, and Cox regression. RESULTS: IDO1, TDO2, and IL4I1 correlated strongly with immune infiltrate density. High IDO1 tumour expression was linked to improved DSS in NSMP and p53mut tumours (p < 0.05), consistent with an "inflamed" phenotype. In contrast, high TDO2 stromal expression predicted reduced DSS in NSMP patients (p < 0.05). Elevated IL4I1 tumour expression was associated with improved DSS in MMRd tumours (p < 0.05). A high CD163:CD8 ratio independently predicted worse DSS in p53mut tumours (p < 0.05). Both TDO2 and IL4I1 were highly expressed high-risk tumours, particularly p53mut cases. CONCLUSIONS: Tryptophan-kynurenine enzymes shape the immune landscape of EC in a subtype-specific manner. High IDO1 was linked to favourable outcomes in p53mut and NSMP cases, whereas TDO2 predicted poor prognosis. The CD163:CD8 ratio emerged as an independent marker of poor survival. These findings support therapeutic strategies combining dual IDO1/TDO2 inhibition or targeting the IL4I1- aryl hydrocarbon receptor (AhR) axis to enhance immunotherapy efficacy in EC.
引用
- Johnson RL, Mappa G, Gahir N, et al. Prognostic and immunological significance of tryptophan metabolic enzymes across endometrial cancer molecular subtypes. Gynecol Oncol. 2025. PMID: 41308228. doi:10.1016/j.ygyno.2025.10.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。